LADENBURG THALM/SH SH initiated coverage on shares of Jaguar Health (NASDAQ:JAGX) in a report issued on Thursday morning, The Fly reports. The firm issued a buy rating and a $5.00 target price on the biotechnology company’s stock.
Several other brokerages have also weighed in on JAGX. Zacks Investment Research lowered shares of Jaguar Health from a buy rating to a hold rating in a research report on Thursday, August 15th. ValuEngine raised Jaguar Health from a hold rating to a buy rating in a report on Thursday, August 1st. Finally, HC Wainwright set a $10.00 price objective on Jaguar Health and gave the stock a buy rating in a report on Tuesday, July 2nd.
NASDAQ:JAGX traded up $0.02 during trading hours on Thursday, hitting $1.33. 1,172,425 shares of the company traded hands, compared to its average volume of 440,586. The company has a quick ratio of 0.24, a current ratio of 0.35 and a debt-to-equity ratio of 0.02. The firm’s 50-day simple moving average is $1.36 and its 200-day simple moving average is $1.54. Jaguar Health has a one year low of $1.00 and a one year high of $175.00. The company has a market cap of $51.00 million, a PE ratio of -0.01 and a beta of 0.74.
About Jaguar Health
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Featured Article: Does the discount rate affect the economy?
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.